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Objectives The purpose of this study was to evaluate the performance of CoreValve Revalving
System (CRS) (Medtronic, Minneapolis, Minnesota) implantation in patients with failed aortic
bioprostheses.
Background Transcatheter aortic valve implantation with the CRS is an effective option in high-risk
patients with severe aortic stenosis. It may be an option for patients with a failed aortic bioprosthe-
sis, especially when the risk of a surgical redo is deemed prohibitive.
Methods CRS “valve-in-valve” implantation was performed in 25 high-risk patients with a failed bio-
prosthesis. Their mean age was 82.4  3.2 years. New York Heart Association functional classes III
and IV were present in 21 and 4 patients, respectively. The logistic EuroSCORE was 31.5  14.8%,
whereas the Society of Thoracic Surgeons score was 8.2  4.2. Patients/prostheses were divided in
type A (mainly stenotic, n  9) and type B (mainly regurgitant, n  16).
Results The implantation success rate was 100%. In group A, the peak aortic gradient signiﬁcantly
decreased from 77.6  21.6 mm Hg to 34.6  19.4 mm Hg (p  0.001). In all but 2 patients in
group B, no signiﬁcant regurgitation was observed post-implantation. No patients died during the
procedure. At 30 days, there were 3 deaths (12%), 2 myocardial infarctions (8%), and 3 atrioventricu-
lar blocks requiring pacemaker implantation (12%). At a mean follow-up of 6 months, there were
another death (survival rate of 84%) and a pacemaker implantation (cumulative incidence of 16%).
New York Heart Association functional class improved in all patients to I and II.
Conclusions CRS implantation was feasible and effective regardless of the prevalent mode of fail-
ure. This ﬁnding may signiﬁcantly affect the treatment of patients with a failed bioprosthesis
deemed at a prohibitive risk for surgical redo. (J Am Coll Cardiol Intv 2011;4:1228–34) © 2011 by
the American College of Cardiology Foundation
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1229Surgical valve replacement has been the treatment of choice
for patients with severe aortic stenosis or regurgitation for
decades (1). Aortic prostheses can be basically divided into
mechanical or biological, each having specific indications as
well as inherent advantages and drawbacks.
Mechanical prostheses, having longer durability, re-
quire lifelong oral anticoagulation therapy. On the other
hand, bioprostheses, although not requiring prolonged oral
anticoagulation therapy, are invariably destined to deterio-
rate (1).
So far, the treatment of choice for a failed bioprosthesis
has been a surgical redo, despite the higher mortality and
morbidity compared to the first surgical treatment, as a
consequence of comorbidities and technical hurdles (2).
Transcatheter aortic valve implantation (TAVI) is currently
considered a valid option for patients with severe aortic stenosis
deemed at prohibitive surgical risk to improve survival and
quality of life compared with medical therapy (3).
Although neither the CoreValve Revalving System
CRS) (Medtronic, Minneapolis, Minnesota) nor the Ed-
ards SAPIEN Transcatheter (EST) heart valve (Edwards
ifesciences, Irvine, California) have been approved for use
n patients with failed aortic bioprostheses, there are reports
f successful implantation in patients refused by surgeons
or an unreasonable surgical risk (4–9).
We report a multicenter experience with CRS valve-in-
alve implantation for a failed aortic bioprosthesis.
ethods
Patients. Valve-in-valve implantation with the CRS for
aortic bioprosthesis failure was performed in 25 patients
(Table 1) at 8 Italian centers with a high volume of TAVIs.
Before the procedure, a thorough evaluation by the heart
team, which included cardiologists, interventional cardiolo-
gists, anesthesiologists, and cardiac surgeons, was performed
to determine surgical eligibility.
Clinical criteria for high risk were considered to be age 75
years and older, coronary artery disease, malignancy, hepatic
cirrhosis, frailty, chronic obstructive pulmonary disease,
severe pulmonary hypertension, porcelain aorta, low ejection
fraction, diabetes, renal failure, and peripheral obstructive
artery disease. The logistic EuroSCORE and STS score
were calculated.
At the time of enrollment in study, all patients had
symptomatic heart failure (New York Heart Association
functional classes III and IV) despite intense medical
therapy. Echocardiographic criteria for bioprosthesis dys-
function were aortic valve area 1 cm2 and/or aortic
regurgitation grade of 3 or higher.
Once consensus on the therapeutic approach and in-
formed written consent were obtained, evaluation of the
patient was performed to select the vascular access and to
assess the presence of coronary artery disease. Percutaneous tcoronary revascularization, when indicated, was performed
before TAVI.
Procedure. Implantation of a third-generation 18-F CRS
Medtronic) was performed in all patients. A transfemoral
r axillary approach was chosen on the basis of anatomic
onsiderations (vessel diameter, tortuosity, calcification, sig-
ificant stenosis). General anesthesia or sedation was left to
he anesthesiologist’s discretion. A temporary pacemaker
as placed in all patients in the absence of a previous
ermanent one. Valvuloplasty during rapid pacing before
RS implantation was optional. Cardiopulmonary support
as not used. The CRS size was chosen according to
ominal internal diameter of the failed prosthesis.
Transthoracic echocardiography was performed post-
rocedure and at hospital discharge. Clinical follow-up
valuation was performed at 30 days, 3 and 6 months, and
hen yearly thereafter.
Double antiplatelet therapy was administered in all pa-
ients. Acetylsalicylic acid was continued indefinitely and
lopidogrel (75 mg/day) for the next 6 months. For patients
reviously treated with percutane-
us coronary intervention (PCI),
ual antiplatelet therapy was con-
inued as planned.
Deﬁnitions. Endpoint definitions
ere according to Valve Aca-
emic Research Consortium con-
ensus document criteria (10).
afety and efficacy endpoints were
ecorded in the hospital, at 30
ays, and at last follow-up.
Statistical analysis. Numerical
alues are expressed as mean SD.
Continuous variables were com-
pared between groups using the paired t test (for normally
distributed variables) or the Mann-Whitney U test (for
non-normally distributed variables). All reported probability
values were 2 tailed, and p  0.05 was considered statisti-
cally significant. Analyses were performed with the SPSS
statistical software package, version 17 (SPSS, Inc., Chi-
cago, Illinois).
Results
The mean age of the patients was 82.4 3.2 years (10 men, 15
omen). The mean logistic EuroSCORE was 31.5  14.8,
hereas the mean STS score was 8.2  4.2 (see Tables 1 and 2
or baseline clinical and echocardiographic characteristics).
atients were further characterized according to the cause of
ailure: predominantly stenosis (group A, n  9, 36%) and
redominantly regurgitation (group B, n  16, 64%).
ighteen prostheses were stented, 7 were stentless. Among
Abbreviations
and Acronyms
CRS  CoreValve Revalving
System
EST  Edwards SAPIEN
transcatheter
OA  orifice area
STS  Society of Thoracic
Surgeons
TAVI  transcatheter aortic
valve implantationhe stentless bioprostheses, the most frequent cause of
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1230failure was regurgitation (6 of 7, 86%), while, among
stented, regurgitation was predominant in 10 cases (55%).
General anesthesia was chosen in 10 patients and deep
sedation in the remaining 15. In 22 patients, a transfemoral
approach was used and a left axillary approach in the remaining
3 patients. Surgical access was preferred in 9 patients; a ProStar
XL device achieved successful hemostasis in 16 patients.
Balloon valvuloplasty was performed in 8 patients (6 in
group A, 2 in group B), post-dilation in 3 patients (2 in
group and 1 in group B). CRS 26-mm was implanted in the
majority of patients (n  19, 76%), and no patient needed
a second CRS implantation.
Procedural outcome. Valve-in-valve implantation was suc-
cessful with immediate restoration of satisfactory valve
function in all but 1 patient in whom, after CRS implan-
tation in a stentless bioprosthesis (Cryolife 25), an acute left
main occlusion occurred that was successfully treated with
PCI. No intraprocedural deaths occurred.
Two patients died (8%) during hospitalization. The first
patient died of cardiogenic shock due to ostial left main
occlusion 48 h after a 26-mm CRS implantation in a
Mitraflow 21 stenotic prosthesis. Urgent coronary angiog-
Table 1. Clinical Characteristics at Baseline
Patient #
Age,
yrs
Logistic
EuroSCORE
STS
Score
NYHA F
Cl
1 83 62.29 13.9
2 77 25.78 7.5
3 77 10.06 2.9
4 82 28.98 10.3
5 76 38.00 5.2
6 87 31.94 7.3
7 81 29.00 11.0
8 84 31.84 16.3
9 81 11.31 17.4
10 81 25.73 4.0
11 86 29.19 10.8
12 79 23.33 5.5
13 81 21.16 4.9
14 78 29.00 8.5
15 84 51.00 8.1
16 85 31.80 6.0
17 83 56.10 10.4
18 82 16.00 7.6
19 83 57.70 6.0
20 87 29.04 9.7
21 80 21.30 10.4
22 87 62.00 11.0
23 78 34.00 5.7
24 85 44.00 10.0
25 84 41.00 4.1
COPD chronic obstructive pulmonary disease; eGFR estimated gl
New York Heart Association; STS Society of Thoracic Surgeons.raphy showed a Mitraflow leaflet overriding the left mainostium, significantly impairing blood flow. Despite pro-
longed attempts, PCI was not successful. The second
patient was urgently admitted with cardiogenic shock due to
a severely stenotic Mitraflow 21 and died of multiorgan
failure 17 days after a successful CRS implantation. No
intraprocedural and periprocedural cerebrovascular events
occurred. Three patients (12%) required pacemaker implan-
tation during hospitalization. A third patient died on day 26
post-procedure of acute heart failure (see Table 3 for 30-day
follow-up, according to Valve Academic Research Consor-
tium recommendations [10]).
Echocardiographic ﬁndings post-TAVI. In group A, the
transaortic gradient significantly decreased from 77.6 
21.6 mm Hg to 34.6 19.4 mm Hg (p 0.0004), whereas
he valve area increased from 0.5  0.1 to 1.5  0.2 (p 
NS). The left ventricular ejection fraction did not signifi-
cantly change before and after procedure (56.5  12.5
before and 53.5  10 after procedure, p  NS). Post-
procedural regurgitation grade was mild in 2 patients (Table 4).
Notably, even in group B, the peak transaortic gradient
significantly decreased from 36.8  22.4 mm Hg to 20.2 
7.2 mm Hg (p  0.01). Regurgitation grade post-
nal
COPD
Renal Function,
eGFR ml/h
Previous Coronary
Revascularization
No 25.0 No
No 26.7 Yes
No 97.2 No
No 18.9 No
Yes 71.0 No
Yes 30.3 Yes
No 67.0 No
Yes 42.0 No
No 39.1 No
No 26.6 No
No 31.4 No
No 37.1 Yes
No 69.0 Yes
No 73.0 No
Yes 26.4 No
No 46.7 Yes
No 24.9 Yes
Yes 30.0 Yes
Yes 41.7 No
No 44.0 No
No 55.0 Yes
No 40.0 Yes
Yes 38.0 Yes
No 35.0 Yes
No 42.0 Yes
ar filtration rate according to Cockcroft-Gault formula; NYHAunctio
ass
3
3
3
3
3
3
4
4
3
3
3
3
3
3
3
3
3
3
3
3
4
3
3
4
3
omerulimplantation was 0 or 1 in 14 patients (87.5%) compared with
not av
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1231100% of patients having a baseline regurgitation grade of 3 or 4.
The ejection fraction did not significantly change (Table 4).
Follow-up. At a mean follow-up of 6 months (median 90
days), there was another death as a result of severe respira-
tory insufficiency. Pacemaker implantation for a new com-
plete atrioventricular block was also required. There were no
additional strokes, myocardial infarcts, major bleeds, or
repeat valve interventions (Table 3). Echocardiographic
parameters at last follow-up showed a persistent good result
after valve implantation (Table 4). New York Heart Asso-
ciation functional class at last follow-up was I and II in all
patients (Fig. 1).
Table 2. Baseline Echocardiographic Characteristics
Valve Type Stented
Inner
Diameter, mm
Mo
Failu
Sorin Pericarbon M21 Yes 17
Mitroﬂow 21 Yes 17
Carpentier/Edwards 21 Yes 20
Carpentier/Edwards 23 Yes 22
Sorin Pericarbon M23 Yes 19
St. Jude Toronto 23 No 21
Mitroﬂow 21 Yes 17
Biocor 25 Yes 23
Carpentier/Edwards 23 Yes 22
Biocor 25 Yes 23
Biocor 25 Yes 23
St. Jude Toronto 23 No 21
Mosaic 23 Yes 21
Hancock 23 Yes 21
Carpentier/Edwards 21 No 20
Carpentier/Edwards 23 Yes 22
Biocor 25 Yes 23
Cryolife 25 No 23
St. Jude Toronto 23 No 21
Cribier 23 Yes 21
Elan 25 No 23
Mosaic 23 Yes 21
Mosaic 23 Yes 21
Mitroﬂow 21 Yes 17
St. Jude Toronto 23 No 21
AVA aortic valve area; LVEF left ventricular ejection fraction; NA
Table 3. Clinical Events (See Text for Definitions)
At 30 Days
Cumulative Event Rate at
Last Follow-Up
Death 3(12) 4 (16)
Myocardial infarction 2 (8) 2 (8)
Stroke 0 (0) 0 (0)
New-onset renal failure 1 (4) 1 (4)
Deﬁnitive pacemaker 3 (12) 4 (16)Values are n (%).Discussion
After the results of the PARTNER trial (3), TAVI can be
reasonably considered a valid option in patients with severe
aortic stenosis who are deemed at high risk or even
unsuitable for surgery to be able to significantly reduce the
rate of all-cause mortality, cardiovascular mortality, and
repeat hospitalization with respect to medical therapy. All
patients in the TAVI arm were treated for a severe stenosis
of the native aortic valve by means of EST heart valve
implantation. Mortality rates of 5% and 30.7% were ob-
served at 30 days and 1 year, respectively.
Bioprosthetic heart valve durability and the inherent
risks of a surgical redo are matters of concern (1,2).
Indeed, the latter acted as a spur for the application of
TAVI in such an off-label indication, the valve-in-valve
technique, which was feasible and effective in some
preliminary experience (4 –9) as well as reported in a
recent publication by Webb et al. (11). Among a popu-
lation of patients with failed prosthetic heart valves,
Webb et al. performed EST heart valve implantation in
10 patients with a failed aortic bioprosthesis and reported
R
Peak (Mean)
Gradient, mm Hg AVA, cm2 R Grade LVEF, %
65 (48) 0.5 1 30
81 (44) 0.4 1 68
91 (57) 0.7 2 64
76 (53) 0.5 1 49
95 (54) 0.6 1 71
116 (60) 0.27 2 55
41 (28) 0.5 1 50
73 (39) 0.6 1 63
61 (33) 0.45 1 59
38 (19) 1.1 4 59
15 (6) 1.1 4 46
18 (10) 0.95 3 62
25 (18) 0.9 4 55
58 (34) 0.9 3 70
47 (23) 1.09 4 50
65 (36) 1.1 3 70
10 (5) 1.1 4 50
22 (14) 1.2 4 60
19 (12) 1 4 70
80 (20) 1.1 4 46
20 (9) 1.2 4 58
NA NA 3 35
65 (35) NA 4 55
NA NA 4 55
34 (16) NA 3 45
ailable; R predominant regurgitation; S predominant stenosis.de of
re, S/
S
S
S
S
S
S
S
S
S
R
R
R
R
R
R
R
R
R
R
R
R
R
R
R
Rencouraging results. Specifically, they observed a 0%
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1232mortality rate at 30 days as well as at a median follow-up
of 83 days.
A 12.4% mortality rate at 30 days was recently reported
by a multicenter real-world registry (12) in which both CRS
and EST heart valve devices were used for stenosis of the
native aortic valve.
Predictors of early and late mortality in high-risk patients
undergoing CRS implantation for severe stenosis of the
native aortic valve were thoroughly described by Tamburino
et al. (13). They reported 5.4% and 15% mortality rates at
30 days and 1 year, respectively.
In our cohort of CRS valve-in-valve implantation pa-
tients, we observed 12% and 16% mortality rates at 30 days
and at a mean follow-up of 6 months, respectively. Of note,
a 30-day mortality of 12% (n  3) appears higher than
predicted by the STS score that was 8.2  4.2. The latter
was developed in 2007 using STS Adult Cardiac Surgery
Database records for surgical procedures taking place be-
tween January 2002 and December 2006. Operative mor-
tality according to the STS score includes both all deaths
occurring during the hospitalization in which the operation
was performed, even if after 30 days, and those deaths
Table 4. Echocardiographic Characteristics at Last Follow-Up
Group
CRS
Size
Peak (Mean)
Gradient, mm Hg
AVA,
cm2
Regurgitation
Grade LVEF, %
A 26 41 (23) 1.6 0 35
A 26 21 (10) 1.5 0 55
A 26 25 (12) 1.5 0 60
A 26 34 (21) 1.6 0 55
A 26 79 (45) 1.1 2 40
A 26 21 (11) 1.6 0 67
A 26 18 (10) 1.6 0 60
A 26 48 (27) 1.3 2 55
A 29 25 (12) 1.7 0 55
B 26 21 (12) 1.7 2 45
B 26 26 (12) 1.6 0 59
B 26 15 (9) 1.7 0 60
B 26 24 (12) 1.6 0 60
B 29 21 (10) 1.6 1 55
B 26 32 (14) 1.5 1 59
B 29 9 (5) 1.7 0 38
B 26 15 (8) 1.7 1 60
B 29 12 (5) 1.7 0 61
B 29 16 (8) 1.6 0 60
B 26 30 (16) 1.6 1 35
B 26 10 (6) 1.3 0 50
B 29 25 (15) NA 1 40
B 26 28 (17) 1.7 0 55
B 26 20 (12) 1.7 2 50
B 26 NA NA NA NA
Amainly stenotic; Bmainly regurgitant; CRS CoreValve Revalving System; Group group
according to predominant mode of failure; other abbreviations as in Table 2.occurring after discharge from the hospital, but within 30days of the procedure unless the cause of death is clearly
unrelated to the operation.
It is conceivable that a risk score specifically developed
based on data from a surgical population might be insuffi-
cient to reliably predict outcomes in a significantly different
setting such as CRS valve-in-valve procedures. Moreover, in
our cohort, those 3 patients who died after the procedure
were deemed inoperable by the surgeon; thus, any risk score
based on surgical patients would be difficult to apply.
However, despite the inherent limitations, the STS score
and the euroSCORE are still useful tools to approximately
quantify the a priori level of risk.
After the encouraging results of the first experiences
worldwide, several publications have clarified some aspects
of the TAVI procedure. Nonetheless, little is known about
specific technical issues when implanting a CRS in a failed
bioprosthesis.
From the access site point of view, although EST heart
valve implantation was performed in 9 of 10 cases via a
transapical approach (11), CRS implantation was feasible by
using a less invasive transfemoral or axillary approach,
requiring general anesthesia in 40% of the cases.
According to prevalent cause of failure, some procedural
steps deserve further discussion. Indeed, for bioprostheses
presenting as predominantly regurgitant, pre-dilation
seemed unnecessary, even when a significant transvalvular
gradient was present. On the other hand, even for mainly
stenotic bioprostheses, the need for pre-dilation was de-
bated as being affected by the risk of gross disruption of the
bioprosthesis with the subsequent risk of massive regurgi-
tation and/or embolization. Of note, in those cases in which
pre-dilation was done, such events did not occur. Similarly,
post-dilation should be used only for those patients in
whom optimal deployment of the valve was not achieved,
thus determining a significant regurgitation or, rarely, a
significant transvalvular gradient. As a result of this case-
0
5
10
15
20
25
Admission Discharge  Follow up
NYHA 3
NYHA 4
NYHA 2
NYHA 1
Figure 1. NYHA Functional Class at Admission, Discharge,
and Last Follow-Up
New York Heart Association (NYHA) functional class evaluation showing
excellent results at a mean 6-month follow-up.
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1233by-case approach, we achieved an adequate orifice area
(OA) and residual gradient in all cases. The assessment of
the OA was done with both a continuity equation and
anatomically; thus, despite inherent limitations of these
methods, the calculated OAs of the CRS were consistent
with data from the manufacturer. Of note, in some cases,
the OA calculated after CRS implantation appeared larger
than the theoretical area of the failed bioprosthesis. This is
not unexpected with respect to a failed bioprosthesis that
might have an inadequate opening of the leaflets.
Similarly, the OA after CRS implantation could also be
larger than the OA of a normally functioning bioprosthesis
because every type of prosthesis has its own geometry and
physiology, both of which determine the excursion of the
leaflets and thus the effective OA.
Regardless of the specific model of bioprosthesis, matching
the CRS size and the internal diameter of the bioprosthesis is
crucially important, although there are only 2 possible sizes of
the CRS. Of note, the 26-mm CRS was the correct option in
the vast majority of patients in our cohort. Its use was possible
even in those bioprostheses with an inner diameter of 17 mm.
Specifically, after careful evaluation by the heart team consid-
ering the prohibitive surgical risk and the clinical conditions
despite intensive medical therapy, implantation of 26-mm
CRS was chosen to at least significantly reduce the transval-
vular gradient and regurgitation. Of note, an acceptable resid-
ual gradient and OA were achieved.
Figure 2. CoreValve Revalving System Deployment in “Stentless” and “Ste
Diverse appearance of a “stentless” (A and B) compared to a “stented” (C and D)
order to determine the exact position of the aortic valve plane. This manoeuvre is not necesThe presence or absence of a radiopaque sewing ring (i.e.,
a stented or stentless bioprosthesis) also deserve consider-
ation. TAVI for a stented bioprosthesis allows more precise
alignment of the CRS frame compared with a stentless
prosthesis in which the technique is the same as that for
native valves (Fig. 2), although bioprostheses are more often
significantly regurgitant and without calcium.
Of note, in our experience, we observed 2 cases of left
main coronary artery obstruction. The first immediately
after TAVI in a stentless xenograft (Cryolife 25), which was
successfully treated with PCI, and the second, 2 days after
the procedure in a stented bioprosthesis that led to the
exitus of the patient despite the prolonged attempt of PCI
(Mitroflow 21, Sorin S.p.A., Milan, Italy).
As previously suggested (14), these are compelling
cases confirming the need for an accurate evaluation of
the aortic root size, distance between the bioprosthesis
and coronary ostia, and the particular characteristics of
the bioprosthesis. As such, the Mitraflow poses unique
hurdles as being quite tall (13 mm) and having leaflet
tissue mounted externally over the stent instead of
internally as is usual. In other words, with externally
mounted leaflets, in particular if the surgeon opted for a
supra-annular position, the valve-in-valve TAVI may
lead to the compression of these leaflets against the aortic
wall, thus impairing coronary blood flow.
Bioprostheses
osthesis. The “pigtail” catheter (A) has positioned in the noncoronary cusp innted”
biopr
sary with a stented bioprosthesis (C), because of the radiopaque sewing ring.
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1234Electrical disturbances leading to pacemaker implanta-
tion are a known drawback of TAVI (15). In our cohort, we
bserved a 16% rate of pacemaker implantation at 6 months,
hich is even lower with respect to TAVI for native aortic
alve where this percentage can widely vary to as much as
7% (16) with a possible higher risk for CRS compared with
he EST heart valve (17). It has been suggested that stented
ioprostheses might be at lower risk of electric disturbances
eing more rigid, thus limiting the compression of the
onduction system by the frame of the CRS (8); however, in
ur cohort, 4 patients received a pacemaker, 2 with a stented
ioprosthesis and the other with a stentless one. Thus, it can
e presumed that the presence or absence of a sewing ring
oes not make a difference, but the conduction system is
articularly delicate. However, only histopathologic exami-
ations along with electrophysiologic studies might provide
nsight into this phenomenon.
Study limitations. CRS implantation for a failed aortic
ioprosthesis can be reasonably considered an option only in
hose centers where the learning curve is far completed, and
here is a robust experience in the treatment of aortic
tenosis in native valves. This should be regarded before
dvocating a large scale adoption of this technique.
onclusions
In centers with expertise in CRS-TAVI in native stenotic
aortic valves, valve-in-valve implantation for failed aortic
bioprostheses is feasible and effective, with good valve
performance and symptom improvement persisting at mid-
term. Moreover, CRS-TAVI, which was introduced for the
treatment of stenotic aortic valves, proved effective, even in
those patients with predominantly regurgitant xenografts,
meaning that the CRS could be an option in regurgitant
aortic valves.
This technique requires a careful evaluation by an expert
heart team who should always evaluate the clinical status of
the patient as well as the particular anatomy of the aortic
root and specific features of the xenograft.
Because aortic bioprostheses differ in a number of technical
aspects, inherent long-term performance and durability may
significantly vary from one model to another; thus, it is unlikely
that the valve-in-valve approach could be completely addressed
in future large trials. This creates the further need for sharing
experiences and results. To the best of our knowledge, our
cohort is the largest in which the CRS was used in the
treatment of failed aortic bioprostheses.
Our data could be acknowledged as a proof-of-concept,
which may significantly affect the treatment of patients with
a failed aortic bioprosthesis, still considered an off-label
indication, deemed at prohibitive risk for a surgical redo. aReprint requests and correspondence: Dr. Luca Testa, Depart-
ment of Interventional Cardiology, Istituto Clinico S. Ambrogio, Via
L. Faravelli 16, 20149 Milan, Italy. E-mail: luctes@gmail.com.
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